Format

Send to

Choose Destination
J Neurol. 2016 Feb;263(2):322-326. doi: 10.1007/s00415-015-7979-x. Epub 2015 Nov 24.

Rituximab in paediatric onset multiple sclerosis: a case series.

Author information

1
Department of Pharmacology and Clinical Neuroscience, Section of Neurology, Umeå University, 90187, Umeå, Sweden. jonatan.salzer@umu.se.
2
Department of Clinical Neuroscience and Rehabilitation, Sahlgrenska University Hospital, Gothenburg, Sweden.
3
Department for Women's and Children's Health, Neuropaediatric Unit, Karolinska Institute, Stockholm, Sweden.
4
Department of Neurology, Institute of Neuroscience, Uppsala University, Uppsala, Sweden.
5
Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
6
Department of Pharmacology and Clinical Neuroscience, Section of Neurology, Umeå University, 90187, Umeå, Sweden.

Abstract

Paediatric onset multiple sclerosis (POMS) is characterized by high inflammatory activity. No disease modifying treatment has been approved for POMS. The objective of this report was to report the use of rituximab, a B cell depleting monoclonal anti-CD20-antibody, in POMS. This is a retrospective case series at four specialized MS centres in Sweden. Participants were identified through the Swedish MS-registry and our own patient stocks. Data were collected through medical charts review. We identified 14 POMS patients treated with i.v. rituximab 500-1000 mg every 6th to 12th months. Median age at disease onset was 14.7 years, median age at rituximab treatment initiation was 16.5 years, and median treatment duration was 23.6 months. No relapses were reported, and the EDSS scores remained stable or decreased in 13 of 14 cases during rituximab treatment. Beyond 6 months from initiating rituximab treatment, only one new lesion was detected on MRI. No serious AEs were reported. The drug survival was 86%. Our data indicate that rituximab treatment is safe, effective and well tolerated in children with MS. Nine POMS cases treated with rituximab have previously been published. They had higher disease activity pre-rituximab, but similar safety and efficacy outcomes after treatment. An RCT of rituximab in POMS is warranted.

KEYWORDS:

Immunomodulatory treatment; Observational study; Paediatric onset multiple sclerosis; Rituximab

PMID:
26603152
DOI:
10.1007/s00415-015-7979-x
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center